| Identification | Back Directory | [Name]
1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride | [CAS]
1628047-87-9 | [Synonyms]
abt199 int 1
5-dimethyl-3
1-((4-chloro-5
ABT199 intermediate1
ABT-199 Intermeidate1
Venetoclax Intermediate 2
1-biphenyl]-2-yl)methyl)piperazine dihydrochloride
1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine diHCL
1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine hydrochloride
1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine dihydrochloride
1-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazine dihydrochloride
1-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}piperazine dihydrochloride
1-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine dihydrochloride
1-((4-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine 2HCl
Piperazine, 1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]- (Dihydrochloride)
1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]
methyl]-Piperazine, hydrochloride (1:2)
1-((4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydroch
Piperazine, 1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-, hydrochloride (1:2)
1-((4'-chloro-5,5-demethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl-2yl]methyl)piperazine dihydrochloride
1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride
1-((4'-Chloro-5,5-dimethyl-3,4,5,6-tetrah
ydro-[1,1'-biphenyl]-2-yl)methy)piperazine dihydrochloride | [Molecular Formula]
C19H27ClN2.2(HCl) | [MDL Number]
MFCD28334264 | [MOL File]
1628047-87-9.mol | [Molecular Weight]
391.806 |
| Hazard Information | Back Directory | [Uses]
1-{[2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine Dihydrochloride is an intermediate used in the preparation of Venetoclax (A112430), which is a potent and selective BCL-2 inhibitor with potent antitumour activity while sparing platelets. Venetoclax is used to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer. |
|
|